On Monday, SciSparc Ltd (NASDAQ: SPRC ) stock is trading higher with a session volume of 30.86 million compared to an average volume of 7.73 million as per data from Benzinga Pro .

SciSparc announced, as part of its ongoing collaboration with Clearmind Medicine Inc. (NASDAQ: CMND ), the publication of a European patent application submitted by Clearmind under the European Patent Office for combination therapy of MEAI and N-Acylethanolamines for binge behavior, including alcohol consumption, eating, tobacco consumption, shopping, and sexual conduct .

Under the collaboration, SciSparc and Clearmind are researching combination therapies that integrate psychedelic molecules with the N-acylethanolamines family, including Palmitoylethanolamide.

To date, Clearmind has filed thirteen patents related to this collaboration in the United States and several other global jurisdictions.

Earlier, Clearmind Medicine filed a patent application for its combination therapy involving Ibogaine and N-Acylethanolamines. It combines the psychedelic compound Ibogaine with Palmitoylethanolamide, which is a member of the N-Acylethanolamines family. It aims to improve the safety and efficacy of Ibogaine-based treatments .

In September, the FDA approved SciSparc’s investigational new drug (IND), which enables the company to proceed to Phase 2b trial for its medication to treat Tourette Syndrome .

Price Action: At the last check on Monday, SPRC stock was 152.90% at $1.39, and CMND stock was up 10.70% at $1.65.

Read Next:

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily , plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga?

This article Why Is Psychedelic-SciSparc Stock Trading Higher On Monday? originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.